{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:29:27Z","timestamp":1775312967230,"version":"3.50.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic stem cell transplantation is an established treatment for hematological malignancies and some genetic diseases. Acute graft-versus-host disease (GVHD) is the most common and debilitating side effect with poor survival rates of 5% to 30% for severe cases. In this manuscript, we describe a tetravalent T-cell\u2013engaging bispecific antibody (BsAb) based on the immunoglobulin G-[L]-single-chain variable fragment (IgG-[L]-scFv) platform, with all 4 binding domains specific for CD3. In\u00a0vitro, picomolar concentrations of the CD3\u00d7CD3 BsAb induced potent lysis of activated CD4 and CD8\u00a0T cells. In immunodeficient mice, in which human T cells induced xenogeneic GVHD, administration of 0.1\u00a0\u03bcg BsAb per dose depleted the majority of T cells from the peripheral blood, and 10\u00a0\u03bcg per dose completely reversed established GVHD and achieved a 100% survival rate. In mice bearing NALM6-luc xenografts, treatment with CD3\u00d7CD19 BsAb and activated human T cells induced complete remission of the leukemia, and all treated mice developed GVHD by 50\u00a0days after treatment. CD3\u00d7CD3 BsAb (3-30\u00a0\u03bcg doses) reversed clinical signs of GVHD, allowing long term follow-up beyond 250\u00a0days. T cells were undetectable by polymerase chain reaction in 4\u00a0of 5 mice in the 30\u00a0\u03bcg CD3\u00d7CD3 BsAb group 180\u00a0days after leukemia injection, and complete necropsies on day 259 revealed no evidence of human T cells or leukemia cells. Curing GVHD allows for long-term follow-up of tumor response heretofore impossible in humanized mouse models. Further studies are warranted to determine whether the CD3\u00d7CD3 BsAb has potential for treating clinical GVHD and other autoimmune diseases in humans.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2022009187","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T21:16:43Z","timestamp":1726694203000},"page":"116-126","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-556X","authenticated-orcid":false,"given":"Madelyn","family":"Espinosa-Cotton","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-4571","authenticated-orcid":false,"given":"Sayed Shahabuddin","family":"Hoseini","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-0515","authenticated-orcid":false,"given":"Ileana C.","family":"Miranda","sequence":"additional","affiliation":[{"name":"2Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Herrick","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-5171","authenticated-orcid":false,"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"2025011416213317000_bib1","first-page":"105","article-title":"Hematopoietic stem cell transplantation","volume":"3","author":"Hatzimichael","year":"2010","journal-title":"Stem Cells Cloning"},{"issue":"35","key":"2025011416213317000_bib2","article-title":"Acute graft versus host disease","volume":"2","author":"Jacobsohn","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2025011416213317000_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2004-11-4557","article-title":"Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study","volume":"106","author":"Cahn","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2025011416213317000_bib4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2004-03-0854","article-title":"Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial","volume":"104","author":"Lee","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2025011416213317000_bib5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2141.2006.06321.x","article-title":"Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease","volume":"135","author":"Bordigoni","year":"2006","journal-title":"Br J Haematol"},{"key":"2025011416213317000_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/2326-6066.CIR-14-0230-T","article-title":"Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody","volume":"3","author":"Xu","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2025011416213317000_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ijc.29007","article-title":"Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy","volume":"136","author":"Cheng","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"2025011416213317000_bib8","doi-asserted-by":"crossref","first-page":"1893500","DOI":"10.1080\/2162402X.2021.1893500","article-title":"A\u00a0novel multimeric IL15\/IL15R\u03b1-Fc complex to enhance cancer immunotherapy","volume":"10","author":"Xu","year":"2021","journal-title":"OncoImmunology"},{"issue":"7","key":"2025011416213317000_bib9","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/leu.2015.20","article-title":"Inducible T-cell receptor expression in precursor T cells for leukemia control","volume":"29","author":"Hoseini","year":"2015","journal-title":"Leukemia"},{"issue":"22","key":"2025011416213317000_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood.V128.22.282.282","article-title":"PI3K\u03b4 inhibition suppresses central nervous system involvement of acute lymphoblastic leukemia","volume":"128","author":"Yao","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025011416213317000_bib11","doi-asserted-by":"crossref","first-page":"e002222","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex\u00a0vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"2025011416213317000_bib12","doi-asserted-by":"crossref","first-page":"e003114","DOI":"10.1136\/jitc-2021-003114","article-title":"Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy","volume":"9","author":"Lin","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"534","key":"2025011416213317000_bib13","doi-asserted-by":"crossref","first-page":"eaax1315","DOI":"10.1126\/scitranslmed.aax1315","article-title":"Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies","volume":"12","author":"Santich","year":"2020","journal-title":"Sci Transl Med"},{"issue":"12","key":"2025011416213317000_bib14","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/2326-6066.CIR-19-0121","article-title":"Silencing Fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2025011416213317000_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine release syndrome: grading, modeling, and new therapy","volume":"11","author":"Liu","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"2025011416213317000_bib16","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.4049\/jimmunol.1301523","article-title":"Preclinical in\u00a0vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?","volume":"191","author":"van der Stegen","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2025011416213317000_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3181\/00379727-75-18083","article-title":"Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins","volume":"75","author":"Kaliss","year":"1950","journal-title":"Proc Soc Exp Biol Med"},{"issue":"9","key":"2025011416213317000_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00277-020-04193-1","article-title":"Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis","volume":"99","author":"Fante","year":"2020","journal-title":"Ann Hematol"},{"issue":"25","key":"2025011416213317000_bib19","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2025011416213317000_bib20","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood.V128.22.3431.3431","article-title":"Pre-transplant low dose cyclophosphamide enhances engraftment and immune reconstitution in haploidentical hematopoietic stem cell transplant (HCT) recipients receiving total body radiation (TBI) free reduced intensity conditioning with post- transplant cyclophosphamide (PTCY)","volume":"128","author":"Khaled","year":"2016","journal-title":"Blood"},{"key":"2025011416213317000_bib21","doi-asserted-by":"crossref","first-page":"761448","DOI":"10.3389\/fimmu.2021.761448","article-title":"T\u00a0cell subsets in graft versus host disease and graft versus tumor","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2025011416213317000_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bmt.2016.225","article-title":"Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease","volume":"52","author":"Garcia-Cadenas","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"2025011416213317000_bib23","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025011416213317000_bib24","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"Oncol"},{"issue":"3","key":"2025011416213317000_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2025011416213317000_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/116\/2349905\/blooda_adv-2022-009187-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/116\/2349905\/blooda_adv-2022-009187-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:21:47Z","timestamp":1736871707000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/116\/517881\/Targeting-T-cells-with-tetravalent-bispecific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009187","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}